Treatment of chronic hepatitis B

Viral Hepatitis

Volumn , Issue , 2007, Pages 323-336

  Marcellin, Patrick ^a   Asselah, Tarik ^a   Boyer, Nathalie ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

Adefovir dipivoxil; Chronic hepatitis B; Entecavir; Lamivudine therapy; Pegylated IFN

Indexed keywords

EID: 36049010058     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987131.ch20     Document Type: Chapter

References (65)

1. Conjeeveram HS, Lok AS. Management of chronic hepatitis B. J Hepatol 2003;38(Suppl. 1)):S90-S103.
2. EASL International Consensus Conference on Hepatitis B. Consensus Statement (long version). J Hepatol 2003;39(Suppl. 1)):S3-S25.
3. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: summary of a workshop. Gastroenterology 2001;120:1828-53.
4. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997;226:347-56.
5. Wong DKH, Cheung AM, O’Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1993;119:312-23.
6. Brunetto MR, Aragon Rodriguez U, Bonino F. Hepatitis B virus mutant. Intervirology 1999;42:69-80.
7. Bonino F, Brunetto M. Chronic hepatitis B e antigen (HBeAg) negative, anti-Hbe negative: an overview. J Hepatol 2003; 39(Suppl. 1):S160-S163.
8. Thomas H, Foster G, Platis D. Mechanisms of action of interferon and nucleoside analogues. J Hepatol 2003;39(Suppl. 1)):S93-S98.
9. Thomas HC, Karayiannis P, Brook G. Treatment of hepatitis B virus infection with interferon. Factors predicting response to interferon. J Hepatol 1991;13:S4-S7.
10. Lai CL, Chien RW, Leung NWY et al. and the Asia Hepatitis Lamivudine Study Group. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-8.
11. Dienstag JL, Schiff E, Wright T et al. for the US Lamivudine Investigator Group. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63.
12. Schalm SW, Heathcote J, Cianciara J et al. International Lamivudine Study Group. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection:a randomised trial. Gut 2000;46:562-8.
13. Schiff ER, Dienstag JL, Karayalcin S et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol 2003;38:818-26.
14. Perrillo RP, Lai CL, Liaw YF et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 200;36:86-94.
15. Honkoop P, de Man RA, Niesters HGM, Zondervan PE, Schalm SW. Severe acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000;32:635-9.
16. Leung NW, Lai CL, Chang TT et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527-32.
17. Liaw YF, Leung NW, Chang TT et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000;119:172-80.
18. Zoulim F, Trépo C. Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy. J Hepatol 1998;29:151-68.
19. Martinot M, Gervais A, Casteinau C et al. Evaluation of trugene ™ HBV genotyping kit (research use only), sequence based genotyping assay for determination of mutations and viral genotype. Viral hepatitis and liver disease. Proceedings of the X Triennial International Symposium on Viral Hepatitis and Liver Disease, Sydney, 2003. (In press.)
20. Tassopoulos N, Volpes R, Pastore G et al. and the Lamivudine Precore Mutant Study Group. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999;29:889-96.
21. Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002;36:219-26.
22. Lau DT, Khokhar MF, Doo E et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000;32:828-34.
23. Perrillo R, Wright T, Rakela J et al. and the Lamivudine North American Transplant Group. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001;33:424-32.
24. Villeneuve JP, Condreay LD, Willems B et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000;31:207-10.
25. Benhamou Y, Katlama C, Lunel F et al. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 1996;125:705-12.
26. Benhamou Y, Bochet M, Thibault V et al. Long term incidence of hepatitis B virus resistance to lamivudine in HIV-infected patients. Hepatology 1999;30:1302-6.
27. Marcellin P, Chang TT, Lim SG et al. for the Adefovir Dipivoxil 437 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16.
28. Marcellin P, Chang TT, Hadziyannis S et al. Adefovir dipivoxil (ADV) 10 mg: results in consistent histological improvement in HBeAg+ and HBeAg- patients regardless of baseline demographic or disease characteristics. Hepatology 2002;4:1869.
29. Chang TT, Shiffman M, Tong M et al. Durability of the HBe seroconversion after adefovir dipivoxil treatment for chronic hepatitis B. J Hepatol 2004;EASL abstract 424.
30. Marcellin P, Chang TT, Lim SG et al. Adefovir dipivoxil (ADV) mg for the treatment of patients with HBeAg+ chronic hepatitis B: continued efficacy beyond 48 weeks. Hepatology 2002;36:373A.
31. Yang H, Westland CE, Delaney WE et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002;36:464-73.
32. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. for the Adefovir Dipivoxil 438 Study Group. Adefovir dipivoxil for the treatment of hepatitis Be antigen- hepatitis B. N Engl J Med 2003;348:800-7.
33. Hadziyannis S, Tassopoulos N, Chang TT et al. Three year study of adefovir dipivoxil (ADV) demonstrates sustained efficacy in presumed precore mutant chronic hepatitis B (CHB) patients in a long term safety and efficacy study (LTSES). J Hepatol 2004;40 (Suppl. 1):17.
34. Perrillo R, Hann HW, Mutimer D et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus mutant. Gastroenterology 2004;126:81-90.
35. Schiff ER, Neuhaus P, Tillman H et al. Safety and efficacy of adefovir dipivoxil for the treatment of lamivudine resistant HBV in patients post liver transplantation. Hepatology 2001;34(Suppl.)):446A.
36. Benhamou Y, Bochet M, Thibault V et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine- resistant hepatitis B virus: an open-label pilot study. Lancet 2001;358:718-23.
37. Lindsay KL, Trépo C, Heintges T et al. for the Hepatitis Interventional Therapy Group. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.
38. Zeuzem S, Feinman SV, Rasenack J et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-72.
39. Cooksley G, Piratvisuth T, Lee SD et al. Peginterferon alpha 2a (40KDa): an advance in the treatment of hepatitis B e antigenpositive chronic hepatitis B. J Viral Hepat 2003;10:298-305.
40. Schalm SW. Combination therapy for chronic hepatitis B. J Hepatol 2003;39:S146-S150.
41. Janssen HLA, Sentruk H, Zeuzem S et al. Peginterferon alfa 2b and lamivudine combination therapy compared with peginterferon alfa 2b for chronic HbeAg-positive hepatitis B: a randomized controlled trial in 307 patients. Hepatology 2003;38:1323.
42. Lau G, Piratvisuth T, Marcellin P et al. Peginterferon alfa-2a (40KD) (Pegasys) monotherapy and in combination with lamivudine is more effective than lamivudine monotherapy in HBeAg-positive chronic hepatitis B. Hepatology 2004;40:20A.
43. Marcellin P, Lau GK, Bonino F et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351:1206-17.
44. Peters MG, Hann HW, Martin P et al. Adefovir dipivoxil alone and in combination with lamivudine in patients with lamivudine- resistant chronic hepatitis B. Gastroenterology 2004;126:91-101.
45. Sung JJY, Lai JY, Zeuzme S et al. A randomised double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipivoxil (ADV) for treatment naïve patients with chronic hepatitis B (CHB): week 52 analysis. J Hepatol 2003;38(Suppl. 2)):69.
46. Balfour HHJ. Antiviral drugs. N Engl J Med 1999;340:1255-68.
47. De Man RA, Wolters LMM, Nevens F et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B. Hepatology 2001;34:578-82.
48. Yamanaka G, Wilson T, Innaimo S et al. Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob Agents Chemother 1999;43:190-3.
49. Lai CL, Rosmawati M, Lao J et al. Entecavir is superior to lamivudine in reducing HBV DNA inpatients with chronic hepatitis B infection. Gastroenterology 2002;123:1831-8.
50. Wolters LMM, Hansen BE, Niesters HGM, De Hertogh D, De Man RA. Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. J Hepatol 2002;37:137-44.
51. Tassopoulos N, Hadziyannis S, Cianciara J et al. Entecavir is effective in treating patients with chronic hepatitis B who have failed lamivudine therapy. Hepatology 2001;34:340A.
52. Chang TT, Gish R, De Man R et al. Entecavir is superior to lamivudine for the treatment of HBeAg(+) chronic hepatitis B:results of phase III study ETV-022 in nucleoside-naïve patients. Hepatology 2004;40:70A.
53. Colonno RJ, Re Rose, Levine SM et al. Emergence of entecavir resistant hepatitis B virus after one year of therapy in phase II and III studies is only observed in lamivudine refractory patients. Hepatology 2004;40:1146A.
54. Leung N, Gish RG, Wang C et al. A randomized, doubleblind comparison of 3 doses of emtricitabine in patients with chronic hepatitis B given 48 weeks of treatment. Hepatology 2001;34:349A.
55. Wang C, Corey L, Leung N et al. Antiviral activity of 48 weeks of emtricitabine treatment in patients with HBeAg negative/HBV DNA positive chronic hepatitis B. Hepatology 2001;34:323A.
56. Pierra C, Imbach JL, De Clerq E et al. Synthesis and antiviral evaluation of some beta-L-2′, 3′dideoxy-5-chloropyrimidine nucleosides and pronucleotides. Antiviral Res 2000;45:169-83.
57. Lai CL, Myers MW, Pow DM et al. Safe and potent suppression of hepatitis B virus with L-deoxythymidine: results of a doseescalation trial. Hepatology 2001;34:321A.
58. Zhou XJ, Lim SG, Lai CL, Murphy R, Pow DM, Myers MW. Phase 1 dose-escalation pharmacokinetics of L-deoxithymidine in patients with chronic hepatitis B virus infection. Hepatology. 2001;34:629A.
59. Han SH, Leung NWY, Teo EK et al. Results of a one-year international phase Iib trial of LdT, and LdT plus lamivudine, in patients with chronic hepatitis B. J Hepatol 2004;40(Suppl. 1)):16.
60. Aguesse-Germon S, Liu H, Chevallier M et al. Inhibititory effect of 2′fluoro-5-methyl-beta-L-arabinofuranosyl uracil on duck hepatitis B virus replication. Antimicrob Agents Chemother 1998;42:369-76.
61. Peek SF, Cote PJ, Jacob JR et al. Antiviral activity of clevudine against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks. Hepatology 2001;33:254-66.
62. Marcellin P, Mommeja-Marin H, Sacks SL et al. A phase II dose escalating trial of clevudine in patients with chronic hepatitis B. Hepatology 2004;40:140-8.
63. Marcellin P, Leung N, Hann H-W et al. A phase II randomized trial evaluating the safety, pharmacokinetics and anti-viral activity of clevudine for 12 weeks in chronic hepatitis B. Hepatology 2004;Abstract 1129.
64. Buti M, Esteban R. Entecavir, FTC, L-FMAU, LdT and others. J Hepatol 2003;39(Suppl. 1)):S139-S142.
65. Shouval D, Lai CL, Cheinquer H et al. Entecavir demonstrates superior histologic and virologic efficacy over lamivudine in nucleoside-naïve HBeAg(-) chronic hepatitis B: results of phase III trial ETV-027. Hepatology 2004;40:LB07